A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Relapsed or Refractory Multiple Myeloma
BIOLOGICAL: C-CAR088
Safety:TEAEs, The incidence of treatment-emergent adverse events (TEAEs), 30 days
ORR, Overall response rate, 12 months|PFS, Progression free survival, 6 months, 12 months
The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.